Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HRTXNASDAQ:IMMPNASDAQ:PDSBNASDAQ:TRDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHRTXHeron Therapeutics$1.89-1.0%$2.05$1.04▼$3.93$288.35M1.332.26 million shs674,976 shsIMMPImmutep$1.91-3.0%$1.75$1.32▼$3.05$278.93M1.8217,951 shs106,718 shsPDSBPDS Biotechnology$1.36-2.9%$1.23$0.85▼$4.42$62.17M1.4485,923 shs198,711 shsTRDAEntrada Therapeutics$7.66-3.0%$8.35$7.10▼$21.79$290.72M0.04131,857 shs360,715 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHRTXHeron Therapeutics+4.37%+2.14%-18.38%-22.67%-41.59%IMMPImmutep+2.07%0.00%+13.87%+2.07%-29.64%PDSBPDS Biotechnology+2.19%-10.83%+11.11%+5.26%-52.70%TRDAEntrada Therapeutics+1.67%+3.67%-11.63%-33.84%-48.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHRTXHeron Therapeutics3.663 of 5 stars3.50.00.04.22.91.70.6IMMPImmutep1.2868 of 5 stars3.51.00.00.02.50.00.0PDSBPDS Biotechnology1.9205 of 5 stars3.73.00.00.02.60.00.0TRDAEntrada Therapeutics2.7967 of 5 stars3.62.00.00.02.81.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHRTXHeron Therapeutics 3.00Buy$5.50191.01% UpsideIMMPImmutep 3.00Buy$7.00266.49% UpsidePDSBPDS Biotechnology 3.33Buy$9.00561.76% UpsideTRDAEntrada Therapeutics 3.25Buy$25.67235.07% UpsideCurrent Analyst Ratings BreakdownLatest PDSB, TRDA, IMMP, and HRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025TRDAEntrada TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/11/2025HRTXHeron TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/31/2025TRDAEntrada TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/27/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $13.003/13/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $21.003/7/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $21.002/28/2025HRTXHeron TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHRTXHeron Therapeutics$148.52M1.94N/AN/A($0.23) per share-8.22IMMPImmutep$5.14M54.27N/AN/A$1.05 per share1.82PDSBPDS BiotechnologyN/AN/AN/AN/A$0.84 per shareN/ATRDAEntrada Therapeutics$172.22M1.69N/AN/A$7.26 per share1.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHRTXHeron Therapeutics-$110.56M-$0.06N/AN/AN/A-20.31%N/A-12.72%8/5/2025 (Estimated)IMMPImmutep-$28.01MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)PDSBPDS Biotechnology-$42.94M-$0.94N/AN/AN/AN/A-139.57%-67.22%8/12/2025 (Estimated)TRDAEntrada Therapeutics-$6.68M$0.814.82N/AN/A25.53%16.11%10.39%8/12/2025 (Estimated)Latest PDSB, TRDA, IMMP, and HRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025PDSBPDS Biotechnology-$0.25-$0.21+$0.04-$0.21N/AN/A5/8/2025Q1 2025TRDAEntrada Therapeutics-$0.78-$0.42+$0.36-$0.42$10.98 million$8.75 million5/6/2025Q1 2025HRTXHeron Therapeutics-$0.01$0.01+$0.02$0.01$37.08 million$38.90 million3/27/2025Q4 2024PDSBPDS Biotechnology-$0.29-$0.21+$0.08-$0.21N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHRTXHeron TherapeuticsN/AN/AN/AN/AN/AIMMPImmutepN/AN/AN/AN/AN/APDSBPDS BiotechnologyN/AN/AN/AN/AN/ATRDAEntrada TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHRTXHeron TherapeuticsN/A2.281.74IMMPImmutep0.0118.2518.25PDSBPDS Biotechnology0.552.842.84TRDAEntrada TherapeuticsN/A6.596.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHRTXHeron Therapeutics80.01%IMMPImmutep2.32%PDSBPDS Biotechnology26.84%TRDAEntrada Therapeutics86.39%Insider OwnershipCompanyInsider OwnershipHRTXHeron Therapeutics5.86%IMMPImmutep3.07%PDSBPDS Biotechnology9.20%TRDAEntrada Therapeutics8.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHRTXHeron Therapeutics300152.56 million143.33 millionOptionableIMMPImmutep2,021146.04 million141.09 millionOptionablePDSBPDS Biotechnology2045.71 million33.86 millionOptionableTRDAEntrada Therapeutics11037.95 million34.58 millionOptionablePDSB, TRDA, IMMP, and HRTX HeadlinesRecent News About These CompaniesEntrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients ...May 29 at 11:28 PM | morningstar.comEntrada Therapeutics to start DMD trial in Q3 2025May 29 at 11:28 PM | investing.comEntrada Therapeutics Receives EU Authorization to Proceed with ELEVATE-45-201 Clinical Study for Duchenne Muscular Dystrophy, Set to Begin in Q3 2025May 29 at 11:28 PM | nasdaq.comEntrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 SkippingMay 28 at 7:00 AM | globenewswire.comQ2 EPS Estimate for Entrada Therapeutics Raised by AnalystMay 24, 2025 | marketbeat.comHC Wainwright Has Positive Forecast for TRDA Q2 EarningsMay 24, 2025 | americanbankingnews.comWhat is HC Wainwright's Estimate for TRDA Q2 Earnings?May 23, 2025 | marketbeat.comNorthern Trust Corp Has $5.50 Million Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)May 23, 2025 | marketbeat.comQ2 Earnings Forecast for TRDA Issued By HC WainwrightMay 23, 2025 | americanbankingnews.comEntrada Therapeutics' (TRDA) "Buy" Rating Reaffirmed at HC WainwrightMay 23, 2025 | americanbankingnews.comEntrada Therapeutics (NASDAQ:TRDA) Given "Buy" Rating at HC WainwrightMay 22, 2025 | marketbeat.comJanus Henderson Group PLC Acquires 368,908 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)May 17, 2025 | marketbeat.comMPM Asset Management LLC Decreases Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)May 16, 2025 | marketbeat.comQ2 EPS Forecast for Entrada Therapeutics Reduced by AnalystMay 16, 2025 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Purchased by Dimensional Fund Advisors LPMay 16, 2025 | marketbeat.comEntrada Therapeutics (NASDAQ:TRDA) Issues Earnings ResultsMay 12, 2025 | marketbeat.comAnalysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest ResultsMay 11, 2025 | finance.yahoo.comEntrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue EstimatesMay 8, 2025 | zacks.comEntrada Therapeutics Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comEntrada Trims Workforce by 20 Percent to Focus on Advancing DMD, Other CandidatesMay 2, 2025 | precisionmedicineonline.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Sold by Price T Rowe Associates Inc. MDMay 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePDSB, TRDA, IMMP, and HRTX Company DescriptionsHeron Therapeutics NASDAQ:HRTX$1.89 -0.02 (-1.05%) Closing price 04:00 PM EasternExtended Trading$1.91 +0.02 (+1.27%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Immutep NASDAQ:IMMP$1.91 -0.06 (-3.05%) Closing price 04:00 PM EasternExtended Trading$1.92 +0.01 (+0.52%) As of 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.PDS Biotechnology NASDAQ:PDSB$1.36 -0.04 (-2.86%) Closing price 04:00 PM EasternExtended Trading$1.38 +0.01 (+1.10%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.Entrada Therapeutics NASDAQ:TRDA$7.66 -0.24 (-3.04%) Closing price 04:00 PM EasternExtended Trading$7.60 -0.06 (-0.78%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
